Henke Brad R, Consler Thomas G, Go Ning, Hale Ron L, Hohman Dana R, Jones Stacey A, Lu Amy T, Moore Linda B, Moore John T, Orband-Miller Lisa A, Robinett R Graham, Shearin Jean, Spearing Paul K, Stewart Eugene L, Turnbull Philip S, Weaver Susan L, Williams Shawn P, Wisely G Bruce, Lambert Millard H
GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA.
J Med Chem. 2002 Dec 5;45(25):5492-505. doi: 10.1021/jm020291h.
A series of 1,3,5-triazine-based estrogen receptor (ER) modulators that are modestly selective for the ERbeta subtype are reported. Compound 1, which displayed modest potency and selectivity for ERbeta vs ERalpha, was identified via high-throughput screening utilizing an ERbeta SPA-based binding assay. Subsequent analogue preparation resulted in the identification of compounds such as 21 and 43 that display 25- to 30-fold selectivity for ERbeta with potencies in the 10-30 nM range. These compounds profile as full antagonists at ERbeta and weak partial agonists at ERalpha in a cell-based reporter gene assay. In addition, the X-ray crystal structure of compound 15 complexed with the ligand binding domain of ERbeta has been solved and was utilized in the design of more conformationally restrained analogues such as 31 in an attempt to increase selectivity for the ERbeta subtype.
报道了一系列对雌激素受体(ER)β亚型具有适度选择性的基于1,3,5-三嗪的雌激素受体调节剂。化合物1对ERβ与ERα显示出适度的效力和选择性,它是通过利用基于ERβ均相时间分辨荧光(SPA)的结合测定法进行高通量筛选鉴定出来的。随后的类似物制备导致鉴定出如化合物21和43等化合物,它们对ERβ显示出25至30倍的选择性,效力在10 - 30 nM范围内。在基于细胞的报告基因测定中,这些化合物在ERβ上表现为完全拮抗剂,在ERα上表现为弱部分激动剂。此外,已解析出与ERβ的配体结合域复合的化合物15的X射线晶体结构,并将其用于设计更多构象受限的类似物,如化合物31,试图提高对ERβ亚型的选择性。